杨时伦 男 硕士研究生导师 中国科学院深圳先进技术研究院
电子邮件: sl.yang@siat.ac.cn
通信地址: 广东省深圳市南山区学苑大道1068号
邮政编码: 518055
招生信息
招生专业
100706-药理学;
071010-生物化学与分子生物学;
招生方向
缺血性脑卒中的干预靶点与新药开发;
缺血性脑卒中引起血脑屏障功能受损的分子调控机制;
血脑屏障功能异常与中枢神经系统炎症靶向药物研究;
教育背景
工作经历
工作简历
2024-01~现在,中国科学院深圳先进技术研究院,副研究员;
2019-08~2024-01,中国科学院深圳先进技术研究院,助理研究员;
2019-08~2021-08,中国科学院深圳先进技术研究院,博士后;
社会兼职
2023-03-04-2028-04-01,深圳市生物医药促进会药理研究与转化应用专业委员会;
2021-01-01-2022-12-31,中国药学会中国临床药理杂志首届**新苗青年委员会;
专利成果
(1) 畅君雷;杨时伦;马寅仲;朱亚东;左氧氟沙星或其药物可接受盐在制备抗脑缺血再灌注损伤的药物或保健品中的应用,2020-9-16,中国,CN202010972345.9;
(2) 畅君雷;杨时伦;李思梦;一种A-FABP蛋白抑制剂及其应用,2023-01-10,中国,CN202111349737.0;
(3) 畅君雷;杨时伦;李思梦;一种A-FABP单克隆抗体2C6及其制备方法和用途,2022-06-30,中国,CN202210756000.9;
(4) 畅君雷;杨时伦;李思梦;一种A-FABP单克隆抗体2B8及其制备方法和用途,2022-06-30,中国,CN202210755954.8;
(5) 畅君雷;杨时伦;李思梦;余敏;一种分泌抗A-FABP 单克隆抗体3G5 的杂交瘤细胞株及其用途,2022-06-30,中国,CN202210755900.1;
(6) 畅君雷;杨时伦;余敏;李思梦;一种分泌抗A-FABP单克隆抗体4A12的杂交瘤细胞株及其用途,2022-06-30,中国,CN202210755920.9;
(7) 畅君雷;杨时伦;余敏;李思梦;一种分泌抗A-FABP单克隆抗体6C11的杂交瘤细胞株及其用途,2022-06-30,中国,CN202210756655.6;
(8) 何丽庄;徐爱民;廖博雅;畅君雷;杨时伦;李思梦;一种A-FABP 中和单克隆抗体及其制备方法和用途,2022-11-17,中国,CN202211439397.5;
(9) Lai Chong Ruby HOO;Aimin XU;Boya LIAO;Junlei CHANG;Shilun YANG;Simeng LI;AN A-FABP NEUTRALIZING MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOF,2023-11-13,欧洲,EP23209441.7;
(10) Lai Chong Ruby HOO;Aimin XU;Boya LIAO;Junlei CHANG;Shilun YANG;Simeng LI;AN AFABP NEUTRALIZING MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOF,2023-11-10,美国,18/506,988;
发表论文
(1) Yang Shilun; Xu Dingkang; Zhang Dianhui; Huang Xiaowen; Li Simeng; Wang Yan; Lu Jing; Wang Daming; Guo Zhen-Ni; Yang Yi; Ye Dewei; Wang Yu; Xu Aimin; Ruby Lai Chong Hoo*; Chang Junlei* ; Levofloxacin alleviates blood-brain barrier disruption following cerebral ischemia and reperfusion via directly inhibiting A-FABP, European Journal of Pharmacology, 2023, 963;
(2) Yang, Shilun; Wang, Haigang; Yang, Yinglin; Wang, Rui; Wang, Yuehua; Wu, Chunfu*; Du, Guanhua* ; Baicalein administered in the subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage, Biomedicine & Pharmacotherapy, 2019, 117;
(3) Yang, Shilun#; Li, Simeng#; Chang, Junlei* ; Discovery of Cobimetinib as a novel A-FABP inhibitor using machine learning and molecular docking-based virtual screening, RSC Advances, 2022, 12(21): 13500-13510;
(4) Yang, Shilun; Shen, Yanjia; Lu, Wendan; Yang, Yinglin; Wang, Haigang; Li, Li; Wu, Chunfu*; Du, Guanhua* ; Evaluation and Identification of the Neuroprotective Compounds of Xiaoxuming Decoction by Machine Learning: A Novel Mode to Explore the Combination Rules in Traditional Chinese Medicine Prescription, Biomed Research International, 2019, 2019: 0-6847685 ;
(5) Liao, Boya#; Yang, Shilun#; Geng, Leiluo; Zong, Jiuyu; Zhang, Zixuan; Jiang, Mengxue; Jiang, Xue; Li, Simeng; Xu, Aimin; Chang, Junlei*; Hoo, Ruby Lai Chong* ; Development of a therapeutic monoclonal antibody against circulating adipocyte fatty acid binding protein to treat ischemic stroke, British Journal of Pharmacology, 2023, 181(8): 1238-1255;
(6) Yu Min#; Nie Yage#; Yang Jiawen#; Yang Shilun#; Li Rui; Rao Varsha; Hu Xiaoyan; Fang Cheng; Li Simeng; Song Dengpan; Guo Fuyou; Snyder Michael P.; Chang Howard Y.; Kuo Calvin J.*; Xu Jin*; Chang Junlei* ; Integrative multi-omic profiling of adult mouse brain endothelial cells and potential implications in Alzheimer's disease, Cell Reports, 2023, 42(11): 0-113392;
(7) Ma Yinzhong#; Yang Shilun#; He Qianyan; Zhang Dianhui; Chang Junlei* ; The Role of Immune Cells in Post-Stroke Angiogenesis and Neuronal Remodeling: The Known and the Unknown, Frontiers in Immunology, 2021, 12(784098) ;
(8) Ma, Yinzhong#; Wang, Lisha#; Yang, Shilun; Liu, Dongyu; Zeng, Yi; Lin, Lilong; Qiu, Linhui; Lu, Jiahao; Chang, Junlei*; Li, Zhihuan* ; The tissue origin of human mesenchymal stem cells dictates their therapeutic efficacy on glucose and lipid metabolic disorders in type II diabetic mice, Stem Cell Research & Therapy, 2021, 12(385) ;
(9) Ji, Yabin#; Chen, Yiman#; Tan, Xixi; Huang, Xiaowen; Gao, Qiang; Ma, Yinzhong; Yang, Shilun; Yin, Meifang; Yu, Min; Fang, Cheng; Wang, Yu; Shi, Zhu*; Chang, Junlei* ; Integrated transcriptomic and proteomic profiling reveals the key molecular signatures of brain endothelial reperfusion injury, CNS Neuroscience & Therapeutics, 2024, 30(4) ;
科研项目
(1)中华人民共和国科学技术部,重点研发计划战略性科技创新合作重点专项,2023YFE0202200,靶向抑制autotaxin的单克隆抗体治疗药物的研发和药效评估,2023-07 至 2025-06,200万元,在研,参与;
(2)国家自然科学基金委员会,青年科学基金项目,82104167,左氧氟沙星通过靶向抑制A-FABP调控小鼠脑缺血再灌注后血脑屏障损伤和神经炎症的药理机制研究,2022-01 至 2024-12,30万元,在研,主持;
(4)广东省基础与应用基础研究基金委员会,基础研究(面上项目),2024A1515013262,A-FABP蛋白在脓毒症相关脑病中的作用机制和靶向药物研究,2024-01-01 至 2026-12-31,15万元,在研,主持;
(3)深圳市科技创新委员会,基础研究(面上项目),JCYJ20210324101401004,左氧氟沙星对小鼠缺血性脑卒中后血脑屏障损伤和神经炎症的治疗效果和药理机制研究,2021-10 至 2024-10,40万元,在研,主持;
奖励荣誉
2024.01 中国科学院深圳先进技术研究院年度优秀员工,深圳,中国;
2022.01 中国科学院深圳先进技术研究院生物医药与技术研究所科研项目奖,深圳,中国;
2020.01 中国科学院深圳先进技术研究院“优秀青年创新基金”,深圳,中国;